Of the 33 patient derived cancers for which RNA levels have been quantified, 14 of them have significantly less PIP5K1C RNA than their paired normal tissues (Figure 6), suggesting that a significant fraction of cancers will respond to treatment with PIKFYVE inhibitors due to a deficiency of PIP5K1C protein. This evidence concerns the gene PIP5K1C and cancer.